References
- Tauber E, Kollaritsch H, Korinek M et al. Safety and immunogenicity of a Vero-cellderived, inactivated Japanese encephalitis vaccine: a noninferiority, Phase III, randomised controlled trial. Lancet370(9602), 1847–1853 (2007).
- Klade CS. Late stage development of a Vero cell culture derived, purified, inactivated Japanese encephalitis vaccine (IXIARO®, IC51). Presented at: Vaccines Summit London, UK, 16–17 June 2008.
- Frech SA, Dupont HL, Bourgeois AL et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers’ diarrhoea: a Phase II, randomised, double-blind, placebo-controlled field trial. Lancet371(9629), 2019–2025 (2008).
Website
- Intercell AG www.intercell.com